MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2024.286945

Медицинская библиотека · Haematologica · 2025

Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.

Shouse Geoffrey, Chen Canping, Muir Alexandra, Popplewell Leslie, Siddiqi Tanya, Zain Jasmine, Herrera Alex F, Danilova Olga, Roleder Carly, Wang Lili, Spurgeon Stephen E F, Kittai Adam S, Chen Lu, Xia Zheng, Davids Matthew S, Danilov Alexey V

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

Despite advances in targeted and cellular therapies, outcomes for patients with Richter's transformation (RT) and transformed non-Hodgkin lymphoma (tNHL) remain dismal. In this report of a phase I multicenter investigator-sponsored study we describe the safety and efficacy of the combination of copanlisib, a selective, small molecule inhibitor of phosphoinositide- 3-kinase, and nivolumab, an antibody against programmed cell death protein 1. Twenty-seven adult patients with relapsed and/or refractory RT or tNHL were treated with escalating doses of copanlisib IV on days 1, 8, and 15 (dose level [DL] 1 - 45 mg, DL2 - 60 mg) combined with nivolumab 240 mg IV on days 1 and 15 of a 28-day cycle. Three dose-limiting toxicities occurred in two patients treated at DL2, hence 45 mg was determined to be the maximum tolerated dose and utilized in the expansion cohort. The most common treatment-related adverse events were diarrhea and anemia. All patients went off protocol, predominantly because of progressive disease and adverse events (67% and 26% of patients, respectively). The overall response rate (ORR) was 46%. Patients with transformed follicular lymphoma had an ORR of 67% (2 complete responses), with median progression-free survival of 4.4 months (95% confidence interval: 1.4-12.2). Patients with RT had an ORR of 31% (2 complete responses) with a median progression-free survival of 2.0 months (95% confidence interval: 0.7- 4.9). Treatment resulted in downregulation of MYC and NFκB pathways in malignant B cells. Responding RT patients exhibited sustained activation of interferon-α and interferon-γ signaling pathways in CD4+ and CD8+ T cells. Overall, treatment with copanlisib and nivolumab demonstrated manageable toxicity and promising clinical efficacy in tNHL patients.

Для цитирования: Shouse Geoffrey, Chen Canping, Muir Alexandra, Popplewell Leslie, Siddiqi Tanya, Zain Jasmine, Herrera Alex F, Danilova Olga, Roleder Carly, Wang Lili, Spurgeon Stephen E F, Kittai Adam S, Chen Lu, Xia Zheng, Davids Matthew S, Danilov Alexey V. Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.. Haematologica. 2025. DOI: 10.3324/haematol.2024.286945.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.